Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the internatio...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology Jg. 14; H. 10; S. 962 - 970 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.09.2013
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study.
Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166.
124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2–94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9–10·8), and four had no preference (1·7%, 0·5–4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients).
Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients.
F Hoffmann-La Roche. |
|---|---|
| AbstractList | Background: Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Methods: Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166. Findings: 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91.5%, 95% CI 87.2-94.7; p<0.0001). Only 16 patients preferred intravenous trastuzumab (6.8%, 3.9-10.8), and four had no preference (1.7%, 0.5-4.3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0.8%] patients). Interpretation: Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Funding F Hoffmann-La Roche. Summary Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Methods Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov , number NCT01401166. Findings 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2–94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9–10·8), and four had no preference (1·7%, 0·5–4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients). Interpretation Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Funding F Hoffmann-La Roche. Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Methods Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166. Findings 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91 times 5%, 95% CI 87 times 2-94 times 7; p<0 times 0001). Only 16 patients preferred intravenous trastuzumab (6 times 8%, 3 times 9-10 times 8), and four had no preference (1 times 7%, 0 times 5-4 times 3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0 times 8%] patients). Interpretation Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Funding F Hoffmann-La Roche. Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166. 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2-94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9-10·8), and four had no preference (1·7%, 0·5-4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients). Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study.BACKGROUNDSubcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study.Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166.METHODSEligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166.124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2-94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9-10·8), and four had no preference (1·7%, 0·5-4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients).FINDINGS124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2-94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9-10·8), and four had no preference (1·7%, 0·5-4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients).Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients.INTERPRETATIONPatient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166. 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2–94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9–10·8), and four had no preference (1·7%, 0·5–4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients). Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. F Hoffmann-La Roche. Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study. Methods Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered withClinicalTrials.gov, numberNCT01401166. Findings 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2-94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9-10·8), and four had no preference (1·7%, 0·5-4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients). Interpretation Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients. Funding F Hoffmann-La Roche. |
| Author | Verma, Sunil Curigliano, Giuseppe López-Vivanco, Guillermo Barrett-Lee, Peter Müller, Volkmar Fallowfield, Lesley Jenkins, Valerie Scotto, Nana Pivot, Xavier Osborne, Stuart Gligorov, Joseph Knoop, Ann Semiglazov, Vladimir |
| Author_xml | – sequence: 1 givenname: Xavier surname: Pivot fullname: Pivot, Xavier email: xavier.pivot@univ-fcomte.fr organization: CHU Jean Minjoz, Besançon, France – sequence: 2 givenname: Joseph surname: Gligorov fullname: Gligorov, Joseph organization: APHP Hôpital Tenon, Paris, France – sequence: 3 givenname: Volkmar surname: Müller fullname: Müller, Volkmar organization: University Medical Centre Hamburg-Eppendorf, Hamburg, Germany – sequence: 4 givenname: Peter surname: Barrett-Lee fullname: Barrett-Lee, Peter organization: Velindre Cancer Centre, Velindre NHS Trust, Cardiff, UK – sequence: 5 givenname: Sunil surname: Verma fullname: Verma, Sunil organization: Sunnybrook Odette Cancer Centre, Toronto, ON, Canada – sequence: 6 givenname: Ann surname: Knoop fullname: Knoop, Ann organization: Copenhagen University Hospital, Blegdamsvej, Copenhagen, Denmark – sequence: 7 givenname: Giuseppe surname: Curigliano fullname: Curigliano, Giuseppe organization: European Institute of Oncology, Milan, Italy – sequence: 8 givenname: Vladimir surname: Semiglazov fullname: Semiglazov, Vladimir organization: NN Petrov Research Institute of Oncology, pos Pesochny-2, St Petersburg, Russia – sequence: 9 givenname: Guillermo surname: López-Vivanco fullname: López-Vivanco, Guillermo organization: University Hospital Cruces, San Vicente de Barakaldo, Vizcaya, Spain – sequence: 10 givenname: Valerie surname: Jenkins fullname: Jenkins, Valerie organization: Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, UK – sequence: 11 givenname: Nana surname: Scotto fullname: Scotto, Nana organization: F Hoffmann-La Roche Ltd, Basel, Switzerland – sequence: 12 givenname: Stuart surname: Osborne fullname: Osborne, Stuart organization: F Hoffmann-La Roche Ltd, Basel, Switzerland – sequence: 13 givenname: Lesley surname: Fallowfield fullname: Fallowfield, Lesley organization: Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23965225$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkmuL1DAUhousuBf9CUrAL7Mfqrk0TauoyLI6woLi5XPI5QSzdtIxaUfG_-P_NJ3uIgzIzqcm6fs-JznnPS2OQh-gKB4T_IxgUj__QiqBS4orviDsXGDWsLK5V5zk46rkVdMc7daz5Lg4TekaYyII5g-KY8ramlPKT4o_nyI4iBAMINdHlEZtxkEF6MeE8t6HIaoNhGmr7MoHn_LB4PuAeofyMg3j73GldFaidf4BYUjolx--o-XlZ1qu--QHvwEEKnZbpCNkBzIq14toMRVfQjx_gVTmrSGUndLQoaiC7Vc-gUWZb7cPi_tOdQke3XzPim_vLr9eLMurj-8_XLy9Kg2vm6EUtaVCOKGtc1o56nCDheMNbjnVdV1pQarMty1xSinNXVsLJepGO-y0bTk7KxYzdx37nyOkQeZLGOi6uSGSCE4obYhoD5QKIQ6gVrStWUsJy9Kne9Lrfowhv3lSNYzhlky1n9yoRr0CK9fRr1TcytuxZsHLWWBin1JusjR-2E0tT8x3kmA5hUjuQiSnhEjC5C5Essluvue-LXCX783sgzyijYcok_FTsqyPYAZpe38n4fUewXQ5ckZ1P2AL6V8vZKISz5CJQdiOMAFe_R9wwAX-AuwCCII |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_breast_2023_103588 crossref_primary_10_1007_s41669_023_00394_2 crossref_primary_10_1016_j_breast_2017_05_004 crossref_primary_10_1177_2374373518770811 crossref_primary_10_1177_10781552231180875 crossref_primary_10_2217_fon_2019_0368 crossref_primary_10_1016_j_waojou_2019_100030 crossref_primary_10_1007_s13346_023_01318_7 crossref_primary_10_1016_j_breast_2016_07_008 crossref_primary_10_1080_2162402X_2021_1915561 crossref_primary_10_1097_NAN_0000000000000099 crossref_primary_10_1016_j_soin_2019_10_006 crossref_primary_10_1016_j_breast_2021_03_004 crossref_primary_10_1016_j_ejca_2021_03_047 crossref_primary_10_1007_s11523_016_0438_5 crossref_primary_10_1177_1078155220960211 crossref_primary_10_1007_s40199_023_00485_9 crossref_primary_10_1080_19420862_2025_2550757 crossref_primary_10_1093_annonc_mdw685 crossref_primary_10_1016_j_ijpharm_2021_120530 crossref_primary_10_1016_j_breast_2022_03_001 crossref_primary_10_1016_j_bulcan_2018_10_005 crossref_primary_10_1080_17425247_2022_2116425 crossref_primary_10_1080_17425247_2022_2162037 crossref_primary_10_1080_17425247_2023_2184343 crossref_primary_10_1007_s11523_014_0313_1 crossref_primary_10_1080_17425247_2021_1981286 crossref_primary_10_1007_s12094_017_1684_4 crossref_primary_10_1016_j_anndiagpath_2015_04_002 crossref_primary_10_1080_10428194_2017_1349906 crossref_primary_10_1093_annonc_mdv108 crossref_primary_10_1016_S2352_3026_17_30078_9 crossref_primary_10_1007_s11095_017_2229_9 crossref_primary_10_1007_s00520_017_3697_5 crossref_primary_10_1016_j_jconrel_2015_05_270 crossref_primary_10_1016_S1470_2045_20_30636_7 crossref_primary_10_1111_bcp_12662 crossref_primary_10_1016_j_clinthera_2019_11_015 crossref_primary_10_1007_s11095_014_1611_0 crossref_primary_10_1038_s41416_020_01255_z crossref_primary_10_1007_s00432_020_03365_w crossref_primary_10_2217_imt_14_50 crossref_primary_10_1001_jamaophthalmol_2022_1091 crossref_primary_10_1016_j_ejogrb_2017_12_006 crossref_primary_10_1002_cam4_573 crossref_primary_10_1177_1078155221999712 crossref_primary_10_1007_s15015_014_0869_8 crossref_primary_10_1007_s40259_018_0295_0 crossref_primary_10_1080_14737167_2023_2249232 crossref_primary_10_1097_CAD_0000000000000648 crossref_primary_10_1177_10781552221137702 crossref_primary_10_1021_acsami_4c20517 crossref_primary_10_1080_14737167_2019_1554437 crossref_primary_10_1177_17588359241274592 crossref_primary_10_1016_j_ejca_2017_08_019 crossref_primary_10_1016_j_canrad_2014_12_003 crossref_primary_10_1093_annonc_mdu524 crossref_primary_10_1136_lupus_2017_000252 crossref_primary_10_1007_s10637_020_00904_7 crossref_primary_10_1093_annonc_mdu364 crossref_primary_10_1007_s43441_024_00725_3 crossref_primary_10_17225_jhp00111 crossref_primary_10_1002_jcph_1362 crossref_primary_10_1007_s41669_022_00361_3 crossref_primary_10_1007_s40744_014_0007_2 crossref_primary_10_1007_s12325_017_0610_z crossref_primary_10_1016_j_clbc_2023_06_007 crossref_primary_10_2217_cer_2017_0048 crossref_primary_10_1007_s00415_023_11955_0 crossref_primary_10_1016_j_clbc_2019_02_008 crossref_primary_10_1021_jacs_2c04944 crossref_primary_10_1016_j_clml_2024_02_004 crossref_primary_10_1080_14737140_2017_1264876 crossref_primary_10_1177_13524585211003020 crossref_primary_10_1080_03639045_2017_1278768 crossref_primary_10_1111_imr_12392 crossref_primary_10_1007_s10269_014_2443_6 crossref_primary_10_1016_S1470_2045_14_70005_1 crossref_primary_10_1186_s12913_021_06277_8 crossref_primary_10_1016_j_clbc_2024_10_005 crossref_primary_10_1007_s11523_019_00684_y crossref_primary_10_1016_j_jconrel_2025_02_069 crossref_primary_10_1111_cts_70037 crossref_primary_10_1177_1178223418758031 crossref_primary_10_1186_1471_2407_14_924 crossref_primary_10_1093_oncolo_oyae102 crossref_primary_10_1016_j_xphs_2025_103914 crossref_primary_10_1007_s40271_014_0075_y crossref_primary_10_1016_j_annonc_2023_05_009 crossref_primary_10_1007_s00280_013_2289_4 crossref_primary_10_1002_adhm_202404660 crossref_primary_10_1016_j_jconrel_2015_07_016 crossref_primary_10_1016_j_jtocrr_2025_100815 crossref_primary_10_1038_s44222_024_00161_w crossref_primary_10_1634_theoncologist_2017_0079 crossref_primary_10_1002_adma_202308738 crossref_primary_10_1016_j_bulcan_2015_01_007 crossref_primary_10_2147_CEOR_S302682 crossref_primary_10_1007_s00280_021_04296_0 crossref_primary_10_1007_s12094_014_1181_y crossref_primary_10_1038_s41578_019_0156_6 crossref_primary_10_1016_j_breast_2017_01_010 crossref_primary_10_2147_DDDT_S287323 crossref_primary_10_1002_adma_202406604 crossref_primary_10_1016_j_ejca_2017_05_009 crossref_primary_10_1080_14737167_2020_1764353 crossref_primary_10_1159_000365723 crossref_primary_10_1371_journal_pone_0157957 crossref_primary_10_4161_21624011_2014_954929 crossref_primary_10_1016_j_ejca_2025_115709 crossref_primary_10_1080_14737167_2021_1860024 crossref_primary_10_1080_17425247_2019_1568408 crossref_primary_10_12968_bjon_2024_33_Sup17_S1 crossref_primary_10_1007_s10269_014_2444_5 crossref_primary_10_1016_j_jtho_2024_05_005 crossref_primary_10_1016_j_breast_2015_01_002 crossref_primary_10_1016_j_critrevonc_2015_01_007 crossref_primary_10_1016_j_ejca_2017_05_010 crossref_primary_10_2217_fon_2017_0574 crossref_primary_10_1016_j_clbc_2018_01_006 crossref_primary_10_1093_annonc_mdv145 crossref_primary_10_1016_j_esmorw_2025_100121 crossref_primary_10_1080_1061186X_2018_1433681 crossref_primary_10_1016_j_annonc_2025_03_012 crossref_primary_10_1371_journal_pone_0211783 crossref_primary_10_1208_s12249_015_0288_y crossref_primary_10_1016_S1470_2045_20_30536_2 crossref_primary_10_1097_CAD_0000000000000287 crossref_primary_10_1007_s10198_023_01648_w crossref_primary_10_1016_S2352_3026_16_00004_1 crossref_primary_10_12968_bjon_2019_28_10_S15 crossref_primary_10_1080_17425247_2023_2219891 crossref_primary_10_1016_j_xphs_2017_05_030 crossref_primary_10_2147_MDER_S337670 crossref_primary_10_1016_j_ejca_2016_03_087 crossref_primary_10_2147_MDER_S479507 crossref_primary_10_1177_10781552251346908 crossref_primary_10_3389_fphar_2024_1338546 crossref_primary_10_1002_mabi_202000295 crossref_primary_10_3322_caac_21597 crossref_primary_10_1634_theoncologist_2018_0065 crossref_primary_10_1016_S1470_2045_13_70389_9 crossref_primary_10_1016_j_breast_2020_05_001 crossref_primary_10_1007_s40259_016_0162_9 crossref_primary_10_2217_bmt_2021_0003 crossref_primary_10_1016_j_addr_2024_115322 crossref_primary_10_1016_j_breast_2019_10_002 crossref_primary_10_1016_j_breast_2022_10_002 crossref_primary_10_1016_j_gyobfe_2014_09_007 crossref_primary_10_1159_000528586 crossref_primary_10_1371_journal_pone_0227961 crossref_primary_10_1016_j_clbc_2019_01_011 crossref_primary_10_1016_j_jconrel_2018_05_038 crossref_primary_10_1200_OP_24_00804 crossref_primary_10_1007_s12325_024_02985_9 crossref_primary_10_1007_s10269_014_2445_4 |
| Cites_doi | 10.1056/NEJMoa052122 10.1177/0091270012436560 10.1056/NEJM200103153441101 10.1016/S0923-7534(20)32881-7 10.1200/JCO.2005.04.173 10.1016/S0140-6736(07)60028-2 10.1016/S1470-2045(06)70910-X 10.1200/JCO.2011.36.7045 10.1016/S1470-2045(11)70033-X 10.1016/S1470-2045(12)70329-7 10.1016/j.jval.2012.08.489 10.1093/jnci/djp386 10.1200/JCO.2011.35.0868 10.1016/S0140-6736(13)61094-6 10.1056/NEJMoa052306 10.1177/0091270009337512 10.1158/0008-5472.SABCS12-P5-15-07 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Sep 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Sep 2013 |
| CorporateAuthor | for the PrefHer Study Group PrefHer Study Group |
| CorporateAuthor_xml | – name: for the PrefHer Study Group – name: PrefHer Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(13)70383-8 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 970 |
| ExternalDocumentID | 3056616371 23965225 10_1016_S1470_2045_13_70383_8 S1470204513703838 1_s2_0_S1470204513703838 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c568t-76d277f7bdffbaf2f0807f580952b664b714abed91faaab5f967a768bf0fbd953 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 192 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000323942500042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Mon Sep 29 03:22:57 EDT 2025 Sat Sep 27 20:44:53 EDT 2025 Sun Nov 09 13:15:49 EST 2025 Mon Oct 06 18:18:41 EDT 2025 Thu Apr 03 07:08:16 EDT 2025 Tue Nov 18 22:22:50 EST 2025 Sat Nov 29 07:03:39 EST 2025 Fri Feb 23 02:29:55 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Oct 14 19:39:05 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c568t-76d277f7bdffbaf2f0807f580952b664b714abed91faaab5f967a768bf0fbd953 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 23965225 |
| PQID | 1428330919 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1751228179 proquest_miscellaneous_1751227775 proquest_miscellaneous_1429639213 proquest_journals_1428330919 pubmed_primary_23965225 crossref_citationtrail_10_1016_S1470_2045_13_70383_8 crossref_primary_10_1016_S1470_2045_13_70383_8 elsevier_sciencedirect_doi_10_1016_S1470_2045_13_70383_8 elsevier_clinicalkeyesjournals_1_s2_0_S1470204513703838 elsevier_clinicalkey_doi_10_1016_S1470_2045_13_70383_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-09-01 |
| PublicationDateYYYYMMDD | 2013-09-01 |
| PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Ismael, Hegg, Muehlbauer (bib12) 2012; 13 De Cock E, Semiglazov V, Lopez-Vivanco G, et al. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. 13th St Gallen International Breast Cancer Conference 2013; St Gallen, Switzerland; March 13–16, 2013. Abstract 328. bib13 Pivot X, Semiglazov V, Chen S-C, et al. Subcutaneous injection of trastuzumab—analysis of administration time and injection site reactions. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 272. Gligorov J, Azim HA, Ataseven B, et al. SafeHer: a study of assisted- and self-administered subcutaneous trastuzumab (H-subcutaneous) as adjuvant therapy in patients with early HER2-positive breast cancer. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 315TiP. Gianni, Dafni, Gelber (bib4) 2011; 12 Basch, Jia, Heller (bib24) 2009; 101 Romond, Suman, Jeong (bib8) 2012; 72 Piccart-Gebhart, Procter, Leyland-Jones (bib1) 2005; 353 Marty, Cognetti, Maraninchi (bib10) 2005; 23 De Cock E, Tao S, Urspruch A, Knoop A. Potential time savings with trastuzumab subcutaneous (SC) injection vs. trastuzumab intravenous (IV) infusion: results from interviews conducted as part of a time-and-motion study (T&M) across 17 sites. ISPOR 15th Annual European Congress; Berlin, Germany; Nov 3–7, 2012. Abstract RU2. Wang, Zhang, Zhao, Men, Parivar (bib22) 2009; 49 Romond, Perez, Bryant (bib2) 2005; 353 De Cock E, Tao S, Urspruch A, Pivot X, Knoop A. Time savings with trastuzumab subcutaneous (SC) injection vs trastuzumab intravenous (IV) infusion: first results from a time-and-motion study (T&M). 35th San Antonio Breast Cancer Symposium 2012; San Antonio, TX, USA; Dec 4–8, 2012. Abstract P5-15-07. Basch, Iasonos, McDonough (bib23) 2006; 7 Perez, Suman, Davidson (bib6) 2011; 29 Wynne C, Waaka DS, Ellis-Pegler RB, et al. Comparative pharmacokinetics of trastuzumab subcutaneous formulation administered using a proprietary single-use injection device, or manually using a syringe. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 470. Smith, Procter, Gelber (bib3) 2007; 369 (bib18) 1994 bib19 bib17 Perez, Romond, Suman (bib5) 2011; 29 Goldhirsch, Gelber, Piccart-Gebhart (bib7) 2013 Wynne, Harvey, Schwabe, Waaka, McIntyre, Bittner (bib20) 2013; 53 Slamon, Leyland-Jones, Shak (bib9) 2001; 344 10.1016/S1470-2045(13)70383-8_bib16 Wang (10.1016/S1470-2045(13)70383-8_bib22) 2009; 49 Gianni (10.1016/S1470-2045(13)70383-8_bib4) 2011; 12 10.1016/S1470-2045(13)70383-8_bib15 Basch (10.1016/S1470-2045(13)70383-8_bib24) 2009; 101 Wynne (10.1016/S1470-2045(13)70383-8_bib20) 2013; 53 Perez (10.1016/S1470-2045(13)70383-8_bib6) 2011; 29 Goldhirsch (10.1016/S1470-2045(13)70383-8_bib7) 2013 Ismael (10.1016/S1470-2045(13)70383-8_bib12) 2012; 13 10.1016/S1470-2045(13)70383-8_bib21 (10.1016/S1470-2045(13)70383-8_bib18) 1994 10.1016/S1470-2045(13)70383-8_bib11 Perez (10.1016/S1470-2045(13)70383-8_bib5) 2011; 29 Romond (10.1016/S1470-2045(13)70383-8_bib8) 2012; 72 10.1016/S1470-2045(13)70383-8_bib14 10.1016/S1470-2045(13)70383-8_bib25 Piccart-Gebhart (10.1016/S1470-2045(13)70383-8_bib1) 2005; 353 Smith (10.1016/S1470-2045(13)70383-8_bib3) 2007; 369 Slamon (10.1016/S1470-2045(13)70383-8_bib9) 2001; 344 Marty (10.1016/S1470-2045(13)70383-8_bib10) 2005; 23 Basch (10.1016/S1470-2045(13)70383-8_bib23) 2006; 7 Romond (10.1016/S1470-2045(13)70383-8_bib2) 2005; 353 23965224 - Lancet Oncol. 2013 Sep;14(10):914-5 |
| References_xml | – volume: 12 start-page: 236 year: 2011 end-page: 244 ident: bib4 article-title: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial publication-title: Lancet Oncol – ident: bib17 article-title: National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 – reference: De Cock E, Tao S, Urspruch A, Knoop A. Potential time savings with trastuzumab subcutaneous (SC) injection vs. trastuzumab intravenous (IV) infusion: results from interviews conducted as part of a time-and-motion study (T&M) across 17 sites. ISPOR 15th Annual European Congress; Berlin, Germany; Nov 3–7, 2012. Abstract RU2. – volume: 101 start-page: 1624 year: 2009 end-page: 1632 ident: bib24 article-title: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes publication-title: J Natl Cancer Inst – volume: 344 start-page: 783 year: 2001 end-page: 792 ident: bib9 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med – volume: 49 start-page: 1012 year: 2009 end-page: 1024 ident: bib22 article-title: Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials publication-title: J Clin Pharmacol – volume: 369 start-page: 29 year: 2007 end-page: 36 ident: bib3 article-title: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial publication-title: Lancet – reference: De Cock E, Tao S, Urspruch A, Pivot X, Knoop A. Time savings with trastuzumab subcutaneous (SC) injection vs trastuzumab intravenous (IV) infusion: first results from a time-and-motion study (T&M). 35th San Antonio Breast Cancer Symposium 2012; San Antonio, TX, USA; Dec 4–8, 2012. Abstract P5-15-07. – volume: 72 year: 2012 ident: bib8 article-title: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 publication-title: Cancer Res – volume: 13 start-page: 869 year: 2012 end-page: 878 ident: bib12 article-title: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial publication-title: Lancet Oncol – reference: Gligorov J, Azim HA, Ataseven B, et al. SafeHer: a study of assisted- and self-administered subcutaneous trastuzumab (H-subcutaneous) as adjuvant therapy in patients with early HER2-positive breast cancer. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 315TiP. – volume: 353 start-page: 1673 year: 2005 end-page: 1684 ident: bib2 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N Engl J Med – volume: 353 start-page: 1659 year: 2005 end-page: 1672 ident: bib1 article-title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer publication-title: N Engl J Med – volume: 29 start-page: 3366 year: 2011 end-page: 3373 ident: bib5 article-title: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31 publication-title: J Clin Oncol – reference: De Cock E, Semiglazov V, Lopez-Vivanco G, et al. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. 13th St Gallen International Breast Cancer Conference 2013; St Gallen, Switzerland; March 13–16, 2013. Abstract 328. – volume: 23 start-page: 4265 year: 2005 end-page: 4274 ident: bib10 article-title: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group publication-title: J Clin Oncol – volume: 53 start-page: 192 year: 2013 end-page: 201 ident: bib20 article-title: Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer publication-title: J Clin Pharmacol – ident: bib19 article-title: Clinical safety data management: definitions and standards for expedited reporting E2A – reference: Wynne C, Waaka DS, Ellis-Pegler RB, et al. Comparative pharmacokinetics of trastuzumab subcutaneous formulation administered using a proprietary single-use injection device, or manually using a syringe. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 470. – year: 1994 ident: bib18 publication-title: Nomenclature and criteria for diagnosis of diseases of the heart and great vessels – volume: 7 start-page: 903 year: 2006 end-page: 909 ident: bib23 article-title: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study publication-title: Lancet Oncol – volume: 29 start-page: 4491 year: 2011 end-page: 4497 ident: bib6 article-title: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer publication-title: J Clin Oncol – year: 2013 ident: bib7 article-title: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial publication-title: Lancet – ident: bib13 article-title: Herceptin. Summary of product characteristics – reference: Pivot X, Semiglazov V, Chen S-C, et al. Subcutaneous injection of trastuzumab—analysis of administration time and injection site reactions. European Society for Medical Oncology Conference 2012; Vienna, Austria; Sept 28–Oct 2, 2012. Abstract 272. – volume: 353 start-page: 1673 year: 2005 ident: 10.1016/S1470-2045(13)70383-8_bib2 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052122 – volume: 53 start-page: 192 year: 2013 ident: 10.1016/S1470-2045(13)70383-8_bib20 article-title: Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer publication-title: J Clin Pharmacol doi: 10.1177/0091270012436560 – volume: 344 start-page: 783 year: 2001 ident: 10.1016/S1470-2045(13)70383-8_bib9 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med doi: 10.1056/NEJM200103153441101 – ident: 10.1016/S1470-2045(13)70383-8_bib11 – ident: 10.1016/S1470-2045(13)70383-8_bib25 doi: 10.1016/S0923-7534(20)32881-7 – volume: 23 start-page: 4265 year: 2005 ident: 10.1016/S1470-2045(13)70383-8_bib10 article-title: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.173 – volume: 72 issue: suppl year: 2012 ident: 10.1016/S1470-2045(13)70383-8_bib8 article-title: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 publication-title: Cancer Res – year: 1994 ident: 10.1016/S1470-2045(13)70383-8_bib18 – volume: 369 start-page: 29 year: 2007 ident: 10.1016/S1470-2045(13)70383-8_bib3 article-title: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(07)60028-2 – volume: 7 start-page: 903 year: 2006 ident: 10.1016/S1470-2045(13)70383-8_bib23 article-title: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(06)70910-X – volume: 29 start-page: 4491 year: 2011 ident: 10.1016/S1470-2045(13)70383-8_bib6 article-title: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.7045 – volume: 12 start-page: 236 year: 2011 ident: 10.1016/S1470-2045(13)70383-8_bib4 article-title: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70033-X – volume: 13 start-page: 869 year: 2012 ident: 10.1016/S1470-2045(13)70383-8_bib12 article-title: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70329-7 – ident: 10.1016/S1470-2045(13)70383-8_bib16 – ident: 10.1016/S1470-2045(13)70383-8_bib14 doi: 10.1016/j.jval.2012.08.489 – volume: 101 start-page: 1624 year: 2009 ident: 10.1016/S1470-2045(13)70383-8_bib24 article-title: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp386 – volume: 29 start-page: 3366 year: 2011 ident: 10.1016/S1470-2045(13)70383-8_bib5 article-title: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.0868 – ident: 10.1016/S1470-2045(13)70383-8_bib21 – year: 2013 ident: 10.1016/S1470-2045(13)70383-8_bib7 article-title: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(13)61094-6 – volume: 353 start-page: 1659 year: 2005 ident: 10.1016/S1470-2045(13)70383-8_bib1 article-title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052306 – volume: 49 start-page: 1012 year: 2009 ident: 10.1016/S1470-2045(13)70383-8_bib22 article-title: Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials publication-title: J Clin Pharmacol doi: 10.1177/0091270009337512 – ident: 10.1016/S1470-2045(13)70383-8_bib15 doi: 10.1158/0008-5472.SABCS12-P5-15-07 – reference: 23965224 - Lancet Oncol. 2013 Sep;14(10):914-5 |
| SSID | ssj0017105 |
| Score | 2.5189958 |
| Snippet | Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in... Summary Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous... Background: Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous... Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 962 |
| SubjectTerms | Administration, Intravenous Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Breast cancer Breast Neoplasms - drug therapy Cancer therapies Chemotherapy Cross-Over Studies Effectiveness Female Health care Hematology, Oncology and Palliative Medicine Humans Injections, Subcutaneous Intention to Treat Analysis Interviews Metastasis Middle Aged Patients Preferences Receptor, ErbB-2 - analysis Trastuzumab |
| Title | Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204513703838 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204513703838 https://dx.doi.org/10.1016/S1470-2045(13)70383-8 https://www.ncbi.nlm.nih.gov/pubmed/23965225 https://www.proquest.com/docview/1428330919 https://www.proquest.com/docview/1429639213 https://www.proquest.com/docview/1751227775 https://www.proquest.com/docview/1751228179 |
| Volume | 14 |
| WOSCitedRecordID | wos000323942500042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYXYS48H4UlspIHHYPZmPnYYcLglVXPUBVFVj1ZvkprbQ0pWl64P_wPxk7aVZI7BaJS9Sm_uKoM5n5xp7MIPSGlk5AVAHRiTOeZJR5olJhiTFWCVVa5uOC_vknPpmI-bycdgtudZdWubWJ0VDbyoQ18pNYGSwF71a-X_4goWtU2F3tWmjsoQPKkiw8mOK0T_GgvE1hpBlPSCi7fvUGz8mX_uQRTY9B7UVKxHW-6TruGX3Q2f3_vfsH6F7HPvGHVl0eoltu8Qjd-dztrz9Gv6Z92xEMbBbXjTYN0EdXNTWG7xdhKXgTy7pi9UfZXVx5DB_rdfOz-a40jMRdydYah7VePB7NGGlTxDYOu1BXGeuQEb_GJmjeCh-FycdudfwOK7je0i0IqKi7xOBObQX66CyO1XCfoG9no6-nY9I1ciAmL8Sa8MIyzj3X1nutPMhfJNznAugd00WRaU4zuJ4tqVdK6dyXBVcQB2mfeG3LPH2K9hfVwj1HGNiMpRZoaaIyiCyVYFYbbkqtIS4qlBigbCtCaboq56HZxqXs09mC5GWQvKSpjJKXAHvbw5ZtmY9dgGKrH3L7DitYXQmOaBeQ_w3o6s521JLKmsmkRQcwTSMUkKJHdvSopT3_MunhVi3l1Ty9Tg7Q6_5nkGbYMmo1K4wBC10ymt4whgNpBPnyfNcYAdZ_gJ61j1D_P7O0LCAKyF_cfJMv0V0WW5GE_L5DtL9eNe4Vum0264t6NUR7fHYejnMej2IYTcEQHXwcTaaz3yThYUg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqgoAL78dCASOB1B5MY-dhBwkhVFpt1e2qgoJ6M35KlcruskkWwf_hym9knFeFRLtceuC22XjiyJ7xfOOMv0HoOc2dgKgCohNnPEko80TFwhJjrBIqt8zXG_qfRnw8FkdH-cEK-tWdhQlpld2aWC_UdmrCHvlmzQwWg3fL38y-klA1Knxd7UpoNGqx575_g5CteL37Dub3BWM724dbQ9JWFSAmzURJeGYZ555r671WHl5GRNynArAG01mWaE4TpZ3NqVdK6dTnGVcAyrWPvLZ5qBIBS_6lwGQXgj2x1aeUUN6kTNKERyTQvJ-eGNr80P-5TuMNMDMRE3GWLzwL69Y-b-fG_zZaN9H1Fl3jt4053EIrbnIbXdlv8wfuoJ8HfVkVDGgdF5U2FcBjN60KDNfHYat7UdPWYvUHrTCeegw_i7L6UX1RGlrilpK2wGEvGw-33zPSpMAtHHaBNxrrkPFfYhMsa47XQ-dDN994hRU8b-YmBEzQnWCAC3YK9uYsrtl-76KPFzJI99DqZDpxDxAGtGapBdgdqQQiZyWY1YabXGuI-zIlBijpVEaalsU9FBM5kX26XtA0GTRN0ljWmiZB7GUvNmtoTJYJZJ0-yu6MLngVCY52mSD_m6Ar2rWxkFQWTEaNdBCmcS0KkqKXbOFfA-v-pdO1zgzkaT-9DQzQs_42zGb4JNZoVmgDHihnND6nDQdQDPPL02VtBHi3AbrfmGw_zizOM4hy0ofnv-RTdHV4uD-So93x3iN0jdVlV0Iu4xpaLeeVe4wum0V5XMyf1IsORp8v2m5_A1qhvLE |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1JbxMxFLaqgiou7EuggJFAag9uYs9iDxJCqG2UqiWK2NSb8SpVKpmQyQTB_-FP8Ot4nq1Cog2XHrhlMn7jkf2W73negtBzmjkBXgV4J854ElPmiYqEJcZYJVRmma8O9D8d8fFYHB9nkzX0q82FCWGVrU6sFLXNTTgj71eVwSKwblnfN2ERk73h69lXEjpIhS-tbTuNmkUO3fdv4L4Vrw72YK9fMDbc_7A7Ik2HAWKSVCwITy3j3HNtvdfKw4uJAfeJANzBdJrGmtNYaWcz6pVSOvFZyhUAdO0HXtssdIwA9X-FR8DFIUt9twsvobwOn6QxH5BQ8v0se6j_vvtzi0bbIHIiIuI8u3ge7q3s3_DG_7xyN9H1BnXjN7WY3EJrbnobbbxt4gruoJ-Trt0KBhSPi1KbEmCzy8sCw_VJOAJfVuVssfqj3DDOPYafxaL8UX5RGkbiplRtgcMZNx7tv2OkDo1bOuxCPWmsQybAApsgcXO8FSYfufn2S6zgeTM3JSCa7hQDjLA5yKGzuKoCfBd9vJRFuofWp_nUPUAYUJylFuD4QMXgUSvBrDbcZFqDP5gq0UNxyz7SNNXdQ5ORU9mF8QWuk4HrJI1kxXUSyHY6slld3mQVQdrypmxzd8HaSDDAqwj53whd0ejMQlJZMDmoqQMxjSpSoBQdZQMLa7j3L5NutiIhz-bp5KGHnnW3YTfDp7Kas8IYsEwZo9EFYziAZdhfnqwaI8Dq9dD9Wny7dWZRloL3kzy8-CWfog0QV3l0MD58hK6xqhtLCHHcROuLeekeo6tmuTgp5k8q_YPR58sW2997e8V2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preference+for+subcutaneous+or+intravenous+administration+of+trastuzumab+in+patients+with+HER2-positive+early+breast+cancer+%28PrefHer%29%3A+an+open-label+randomised+study&rft.jtitle=The+lancet+oncology&rft.au=Pivot%2C+Xavier&rft.au=Gligorov%2C+Joseph&rft.au=M%C3%BCller%2C+Volkmar&rft.au=Barrett-Lee%2C+Peter&rft.date=2013-09-01&rft.issn=1474-5488&rft.eissn=1474-5488&rft.volume=14&rft.issue=10&rft.spage=962&rft_id=info:doi/10.1016%2FS1470-2045%2813%2970383-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204513X71554%2Fcov150h.gif |